CorMedix Completes Acquisition of Melinta Therapeutics

CorMedix completes $300M acquisition of Melinta Therapeutics

The basics: CorMedix acquires Melinta Therapeutics in $300M deal Acquisition includes milestone payment tied to FDA approval of Rezzayo Melinta’s portfolio generated $120M revenue in 2024, with growth expected Leadership team combines executives from both companies CorMedix Inc. completed its acquisition of Melinta Therapeutics LLC for approximately $300 million, the Berkeley Heights-based biopharmaceutical company announced Sept. 2. Melinta is…

CorMedix Completes Acquisition of Melinta Therapeutics

CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it has successfully completed its previously announced acquisition of Melinta Therapeutics LLC, a private commercial-stage company providing innovative therapies for acute and life-threatening illnesses. “This acquisition is a transformational step in the evolu…